Direkt zum Inhalt
Merck

F9056

Anti-FRAT1 antibody produced in rabbit

~1.5 mg/mL, affinity isolated antibody, buffered aqueous solution

Synonym(e):

Anti-Frequently rearranged in advanced T-cell lymphomas, Anti-GBP, Anti-GSK-3 binding protein

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Ansicht ändern

Über diesen Artikel

NACRES:
NA.41
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
polyclonal
Application:
WB
Citations:
8
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten


biological source

rabbit

conjugate

unconjugated

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

form

buffered aqueous solution

mol wt

antigen ~29 kDa

species reactivity

human

packaging

antibody small pack of 25 μL

enhanced validation

recombinant expression
Learn more about Antibody Enhanced Validation

concentration

~1.5 mg/mL

technique(s)

western blot: 1-2 μg/mL using using rat liver extract (S1 fraction) and a HEK-293T cell lysate expressing human FRAT1.

UniProt accession no.

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... FRAT1(10023)

General description

FRAT1 (frequently rearranged in advanced T-cell lymphomas-1) is a GSK3β binding protein consisting of a conserved GSK3β interacting domain. In human two FRAT genes have been identified, FRAT1 and FRAT2 whereas FRAT1-3 have been identified in mouse.

Application

Anti-FRAT1 antibody produced in rabbit is suitable for western blot at a concentration of 1-2μg/mL using rat liver extract (S1 fraction) and a HEK-293T cell lysate expressing human FRAT1.

Biochem/physiol Actions

By inhibiting GSK-3-mediated phosphorylation of β-catenin, FRAT1 plays a major role in the wnt-signaling pathway. During binding to the GSKβ3, it competes with axin, and thus displacing GSK3β from the axin-β-catenin complex. In the canonical wnt signaling pathway, FRAT1 acts more efficiently than FRAT2. FRAT1 has correlation with clinicopathologic features. It has been reported that in several human malignant tumors, FRAT is overexpressed. It′s upregulated expression have been found in several human cancer lines such as gastric cancers and esophageal squamous cell carcinoma (ESCC).

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.


Still not finding the right product?

oder

Probieren Sie unser Produkt-Auswahlhilfe, um Ihre Auswahl einzugrenzen




Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen


Verwandter Inhalt

Instructions






Global Trade Item Number

SKUGTIN
F9056-25UL04061837720437
F9056-200UL04061835688265